Compare Emerson Electric Co. (EMR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Mesoblast Limited — how do they compare? Emerson Electric Co. trades at $159.06 (market cap $88.72B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Emerson Electric Co. is far larger — about 50.7× Mesoblast Limited's market cap, and Emerson Electric Co. pays a 1.4% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Mesoblast Limited for 14 Days on average.
| EMR | MESO | |
|---|---|---|
Market Cap | $88.72B | $1.75B |
Volume | 2,355,255 | 239,027 |
Sector | Industrials | Health |
52-Week High | $164.38 | $20.96 |
52-Week Low | $123.30 | $13.19 |
Typical Hold Time | 81 Days | 14 Days |
Enterprise Value | $99.80B | $1.83B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected at $18.6B for 2026, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. The stock faces resistance near $160, with support at $158.
Outlook remains positive given earnings momentum and a consensus price target of $165.90, implying ~4% upside. Risks include debt levels rising to 31.26% of assets in 2025 and macroeconomic pressures on industrial demand. Institutional sentiment is bullish, with 53% of analysts rating Buy.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
